We are an Australian translational biomedical research institute with drug, vaccine and diagnostic assets in discovery, preclinical and clinical development; and glycomics platform technologies. Our primary disease areas are infectious diseases and cancer
The Institute for Glycomics is a flagship biomedical research institute at Griffith University’s Gold Coast campus. The purpose-designed building represents a significant investment by the University and the Queensland Government. Located adjacent to the new Gold Coast University Hospital, it is also an integral component of the emerging Gold Coast Health and Knowledge Precinct.
The Institute develops next-generation drugs, vaccines and diagnostics for diseases of global impact. It has an extensive track record of successful partnerships with government and industry and is currently developing a pipeline of technologies in infectious diseases and cancer. The Institute represents a unique national resource with a multi-disciplinary and translational approach with a particular focus in the area of glycoscience and the application of “omics” approaches to the study of carbohydrates in biological systems. It was the 'glycomics approach' that led to the discovery of the world’s first anti-influenza drug, Zanamivir (Relenza) by the Institute’s founding Director, Prof Mark von Itzstein.
We have a broad range of translational research programs and a pipeline of technologies in development. We are particularly interested in speaking to prospective partners about some of our most advanced programs, including:
- Novel lead molecules for the treatment of Parainfluenza;
- Novel lead molecules for the treatment of Hand, Foot and Mouth Disease;
- Improved synthetic method, novel intermediates and access to novel derivatives of fondaparinux (heparin mimetics);
- Malaria vaccine (blood-stage, chemically attenuated whole parasite vaccine, completed First-in-man studies;
- Computational platform for the discovery of peptide inhibitors with application to the discovery of new classes of antimicrobial, antiviral and anticancer drugs;
- A selection of gonococcal vaccine candidate antigens conserved amongst all isolates of Neisseria gonorrhoea;
- A cancer diagnostic/prognostic based upon detection of Neu5Gc using a highly specific and highly sensitive lectin;
- Dengue; and Chikungunya and related emerging alphaviruses (disease models, access to clinical isolates and drug repurposing programs);
- Burkholderia pseudomallei (aerosol infection and in vivo imaging expertise; molecular biology including mutagenesis); and
- Campylobacter (including collection of strains associated with post-infection autoimmune disease (rheumatoid arthritis and Guillain-Barre Syndrome).
We also seek to leverage our unique glyco platforms:
- The Australian Centre for Cancer Glycomics (A2CG) – using advanced MS and MS imaging technologies for systematic and high-throughput discovery of new biomarkers for cancers that are not currently well-informed by other ‘omics ; This advanced platform will provide access to novel drug and vaccine targets and novel candidate therapeutics.
- Integrated Glycan / Lectin Array and Surface Plasmon Resonance Facility for the analysis of carbohydrate/protein (and other) interactions;
- Carbohydrate synthesis; and
- Structure-based drug design (especially carbohydrate-based)
The Fraunhofer International Consortium for Anti-Infective Research (iCAIR) is a partnership with the Fraunhofer Institute for Toxicology and Experimental Medicine and the Hannover Medical School, Germany. We are a fully-integrated preclinical development platform available to external partners with core capabilities in:
- Development of anti-infective compounds for key respiratory bacterial, viral and fungal pathogens;
- Knowledge-based, target identification and rational drug design; and
- Novel ex vivo preclinical models (incl. human precision-cut lung slices) enabling toxicological, efficacy and immunological readouts.